| Title |
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
|
|---|---|
| Published in |
Trials, November 2020
|
| DOI | 10.1186/s13063-020-04876-0 |
| Pubmed ID | |
| Authors |
Timothy Devos, Tatjana Geukens, Alexander Schauwvlieghe, Kevin K. Ariën, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniël Desmecht, David Grimaldi, Bart N. Lambrecht, Anne Luyten, Piet Maes, Michel Moutschen, Marta Romano, Lucie Seyler, Michel Toungouz Nevessignsky, Katleen Vandenberghe, Johan van Griensven, Geert Verbeke, Erika Vlieghe, Jean Cyr Yombi, Laurens Liesenborghs, Peter Verhamme, Geert Meyfroidt |
Mendeley readers
The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 149 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 21 | 14% |
| Student > Master | 16 | 11% |
| Researcher | 9 | 6% |
| Student > Ph. D. Student | 9 | 6% |
| Student > Doctoral Student | 8 | 5% |
| Other | 22 | 15% |
| Unknown | 64 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 26% |
| Nursing and Health Professions | 18 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Social Sciences | 4 | 3% |
| Other | 6 | 4% |
| Unknown | 70 | 47% |